Rana Mazraani
Family · Dearborn, MINPI 1013527167
Payments from drug & device makers
Across 23 payments — averaging $35.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$163
- Novo Nordisk$146
- Lilly USA, LLC$144
- Merz North America, Inc.$110
- GSK$51
- Phadia US Inc.$51
- plus $145 from 6 others
What the payments were for
- Speaking & faculty fees$243%
- Travel & lodging$648%
- Food & beverage$72189%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $163 |
| Novo Nordisk | 3 | $146 |
| Lilly USA, LLC | 2 | $144 |
| Merz North America, Inc. | 1 | $110 |
| GSK | 3 | $51 |
| Phadia US Inc. | 3 | $51 |
| Boston Scientific | 2 | $41 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| IBSA Pharma Inc. | 1 | $20 |
| AstraZeneca | 1 | $15 |
| Revance Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$809 in reported general payments places this provider in the 65th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 35 | $1,176 |
| Lidocaine | 26 | $1,086 |
| Celecoxib | 33 | $905 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $414 |
| Pregabalin | 26 | $363 |
| Gabapentin | 38 | $262 |
| Tizanidine Hcl | 48 | $208 |
| Amlodipine Besylate | 47 | $178 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $166 |
| Ammonium Lactate | 11 | $162 |
| Cyclobenzaprine Hcl | 23 | $152 |
| Atorvastatin Calcium | 18 | $125 |
| Metformin Hcl | 38 | $123 |
| Tramadol Hcl | 12 | $120 |
| Simvastatin | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Other family in Dearborn
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.